TransCode Therapeutics, Inc. (RNAZ)
1.88
-0.01
(-0.53%)
USD |
NASDAQ |
Sep 09, 15:06
TransCode Therapeutics Total Assets (Quarterly) : 151.01M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 151.01M |
| March 31, 2026 | 157.16M |
| December 31, 2025 | 162.40M |
| September 30, 2025 | 5.227M |
| June 30, 2025 | 8.266M |
| March 31, 2025 | 13.19M |
| December 31, 2024 | 7.294M |
| September 30, 2024 | 3.936M |
| June 30, 2024 | 4.825M |
| March 31, 2024 | 7.290M |
| December 31, 2023 | 5.170M |
| September 30, 2023 | 10.23M |
| June 30, 2023 | 5.882M |
| March 31, 2023 | 5.590M |
| Date | Value |
|---|---|
| December 31, 2022 | 7.588M |
| September 30, 2022 | 12.02M |
| June 30, 2022 | 14.16M |
| March 31, 2022 | 18.85M |
| December 31, 2021 | 22.94M |
| September 30, 2021 | 25.37M |
| June 30, 2021 | 1.532M |
| March 31, 2021 | 1.051M |
| December 31, 2020 | 1.068M |
| September 30, 2020 | 1.185M |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 0.2167M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.112B |
| Oncolytics Biotech, Inc. | 7.671M |
| Sangamo Therapeutics, Inc. | 59.96M |
| Sarepta Therapeutics, Inc. | 3.189B |
| Anixa Biosciences, Inc. | 14.86M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 12.65M |
| Shareholders Equity (Quarterly) | 138.36M |
| Debt to Equity Ratio | 0.0047 |
| Current Ratio | 1.971 |
| Net Debt Paydown Yield | -2.08% |